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isk of Sudden Death
n Asymptomatic
rugada Syndrome
ot as High as We Thought and Not as
ow as We Wished . . . But the Contrary*
ami Viskin, MD, Raphael Rosso, MD
el Aviv, Israel
or every 10 patients with Brugada syndrome presenting
ith syncope, 8 will be diagnosed only after a cardiac arrest
1). This 8:10 ratio of deadly to nonlethal events among
onsecutive patients with symptomatic Brugada syndrome is
trikingly higher than the 8:60 ratio of deadly to nonlethal
vents reported for consecutive patients with symptomatic
ong-QT syndrome (2). Thus, although we still do not
now what percentage of patients born with Brugada
yndrome will ever have spontaneous arrhythmias, we do
now that those who do are likely to experience cardiac
rrest. This “1 strike and you’re out” risk called for an
ggressive approach to asymptomatic Brugada syndrome
3). However, widespread use of prophylactic implantable
ardioverter-defibrillator (ICD) devices was soon associated
ith intolerably high rates of complications among young
atients with Brugada syndrome (4,5). Clearly, continuous
eassessment of the tests we use for risk stratification in
rugada syndrome is mandatory.
See page 1576
isk stratification based on electrophysiologic studies.
he weight of risk stratification in Brugada syndrome has
een primarily placed on electrophysiologic study (EPS) (3).
his approach was driven by data from Brugada showing
hat patients with inducible ventricular fibrillation (VF)
ave a 10-fold risk for developing spontaneous VF (6).
ontroversy started, however, when neither Priori et al. (7)
or Eckardt et al. (8) could reproduce such results. Contro-
ersy turned into disappointment when 2 independent
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Telr
viv University, Tel Aviv, Israel. The authors have reported that they have no
elationships to disclose.eta-analysis, of reports published by 2006, showed that
PS is of little value for predicting spontaneous VF (1,9).
urthermore, 2 recent multicenter studies from Europe—
he FINGER (France, Italy, Netherlands, Germany) study
10)—and Japan (11) questioned whether EPS has any
rognostic value in Brugada syndrome.
In both studies (10,11), EPS included programmed
timulation at 2 right ventricular sites with as many as 3
xtrastimuli. However, the minimal coupling interval of the
xtrastimuli (a strong determinant of VF-inducibility rate)
as kept above 200 ms in the FINGER study but was
rought down to ventricular refractoriness in the Japanese
tudy. Consequently, the percentage of asymptomatic pa-
ients who had inducible VF was higher in the Japanese
tudy (57%) than in the FINGER study (37%). However,
he percentage of patients who had spontaneous VF during
ollow-up in the 2 studies was lower than predicted, on the
asis of the numbers published by Brugada et al. (6), and did
ot appear to be influenced by the results of EPS (Fig 1). In
oth studies combined, only 2.6% of asymptomatic patients
ith inducible VF, as well as 1.8% of patients with negative
PS, had spontaneous VF during 4 to 5 years of follow-up
p  0.56). Having said that, it is also premature to
onclude that the long-term risk for patients with asymp-
omatic Brugada syndrome is negligible, because of the
ollowing: 1) Although the 460 patients with asymptomatic
rugada syndrome who underwent EPS in both studies
epresent the largest such cohort ever reported, the limited
opulation size precludes narrowing the confidence interval
f any prediction. Using 95% confidence limits, one can
nly conclude from these studies that the risk for sponta-
eous VF at 4 to 5 years of follow-up is very likely between
% and 6% for asymptomatic adults with Brugada syndrome
nd inducible VF and between 1% and 4% for those with
egative EPS. 2) Although the follow-up periods keep
xpanding, they are still inadequate to allow accurate esti-
ation of the long-term risk for this inborn condition. In
ther words, we simply do not know if a 2.6% risk at 4 years
ranslates into a 26% risk at 40 years. Nevertheless, in view
f the minimal increment in prognostic value provided by
he EPS results, the majority of electrophysiologists are now
ooking elsewhere for prognostication.
linical risk factors. The majority of Brugada patients
ho eventually have VF are male (12). However, 70% of all
ecognized patients with asymptomatic Brugada are also
ale (10). Consequently, sex is a weak prognosticator in
rugada syndrome (10). Importantly, the few females who
ctually have spontaneous VF have less often a type I
rugada electrocardiogram (ECG), have less degree of
T-segment elevation, and data on their response to fle-
ainide or ajmaline challenge are limited (13). Similarly, the
ajority of Brugada patients who have arrhythmias are20
nd60 years of age. Taking into consideration the limited
ccuracy of our prognostic tests and the high complication
ates of ICD implantation (4,5), we believe that clinicians
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Risk of Sudden Death in Asymptomatic Brugada November 2, 2010:1585–8hould “look the other way” when dealing with women,
lderly patients, or children with asymptomatic Brugada
yndrome (14).
lectrocardiographic parameters. Numerous studies have
hown that patients who have spontaneous type I (2 mm
oncave ST-segment elevation) Brugada ECG do worse than
atients who only have a type I pattern when challenged with
sodium-channel blocker (9,10). However, classifying patients
s either type I or non-type I is tricky because of the following:
) Analysis of serial ECG recordings shows that the Brugada
CG pattern is highly variable over time. In patients with
pontaneous coved-type ECG, only every third ECG is
iagnostic, and every third ECG is normal (15). 2) Placing the
1-V2 recording electrodes at the second or third intercostal
pace (in addition to the standard fourth space location)
ncreases the odds for recording a type I pattern (16). 3) With
4-h Holter recordings, one may detect transient type-I
T-segment elevation at night or after heavy meals (17). Thus,
sing Holter recordings with “high V1-V2” electrodes, one may
ouble the percentage of patients with “spontaneous” type I
CG (18). Finally, Brugada patients may have a type I ECG
nly during fever, and may then have a malignant course (19).
The ECG features other than the degree of ST-segment
levation in V1-V2 are important. J-point elevation and
early repolarization” in the inferior leads are observed in
0% of patients with Brugada syndrome (20), and such
atients appear to be at higher risk (11). Also, QRS wider
han 120 ms in V2 (21) and QRS fragmentation in V1-V3
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Figure 1 Outcomes of Patients With Asymptomatic Brugada Sy
*Based on data from 2 recent large prospective studies (10,11). EPS  electrophre more frequently seen in Brugada patients with symp- Soms (22). In 1 study, QRS fragmentation performed better
han EPS as a risk-stratification tool (22).
esponse to exercise. Worsening of ST-segment elevation
uring the recovery phase of exercise tests in Brugada
yndrome has been reported sporadically (23–25). Recently,
min et al. (26) reported J-point elevation in Brugada
atients during exercise and further elevation during the
ecovery period. Now, in this issue of the Journal, Makimoto
t al. (27) report that ST-segment elevation during the
ecovery phase of exercise occurs in one third of Brugada
atients and is a strong predictor of spontaneous VF (27).
The study by Makimoto et al. (27) included 93 patients
ith Brugada syndrome as well as 102 controls (including
7 with right bundle branch block), who underwent stan-
ard exercise testing. The ST-segment elevation in V1-V3
defined as a 0.05 mV from their baseline) within 4 min
f the end of exercise occurred in 37% patients with
rugada syndrome but in none of the controls (p 0.0001).
atients with significant ST-segment rise during recovery also
ad more pronounced heart-rate slowing from peak exercise
uring the recovery period, reflecting greater vagal stimulation
uring recovery. Also, ST-segment elevation during recovery
as associated with a SCN5A mutation, but not with a history
f syncope or cardiac arrest. Importantly, during 6 3 years of
ollow-up, arrhythmic events occurred in 44% of patients with
rugada syndrome who had ST-segment elevation during
ecovery from exercise, but in only 17% of Brugada patients
ho did not (p  0.004). During univariate analysis, “history
f VF,” “ST-segment elevation after exercise,” and “presence of
791
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November 2, 2010:1585–8 Risk of Sudden Death in Asymptomatic Brugadauction of VF at EPS did not. Moreover, only the first 2
arameters remained significant independent predictors of
utcome during multivariate analysis (27). Finally, among the
6 initially asymptomatic Brugada patients, 15 had ST-
egment elevation after exercise, and 3 (20%) of them had
rrhythmic events during follow-up. In contrast, none of the
1 asymptomatic patients without ST-segment elevation after
xercise had arrhythmic events (p  0.039). These results are
n agreement with studies showing that vagal stimulation
uring pharmacologic challenge (28), heavy meals (17), or
agal syncope (29) increases the dispersion of ventricular
epolarization and may be proarrhythmic in Brugada syn-
rome. However, 3 points argue against embracing the exercise
est as the main tool for defining the need for therapy among
symptomatic patients: 1) the test failed to identify 68% of
atients with a history of cardiac arrest; 2) the reproducibility of
he test was not tested; and 3) the study included only 36
atients with asymptomatic Brugada syndrome, and that 8% of
hem had arrhythmic events during follow-up suggests that
his was an a priori high-risk population (for comparison,2%
f initially asymptomatic patients had symptoms in the 2
ecent multicenter studies already noted) (10,11).
hat now? In the absence of well-established and reliable
rognostic tests, we are now recommending prophylactic
rug therapy with quinidine for asymptomatic Brugada
yndrome in the context of an international study (30).
As explained in detail elsewhere (31), there are strong
linical and experimental data suggesting that quinidine
ould do for asymptomatic Brugada syndrome what beta-
lockers have done for asymptomatic long-QT syndrome. It
s, therefore, important to continue all efforts to prevent the
isappearance of quinidine from the market (32–35).
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